Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study.

Zhan Z, Smyth B, Toussaint ND, Gray NA, Zuo L, de Zoysa JR, Chan CT, Jin C, Scaria A, Hawley CM, Perkovic V, Jardine MJ, Zhang L.

BMC Nephrol. 2019 Jul 12;20(1):258. doi: 10.1186/s12882-019-1438-3.

2.

The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes.

Helsby NA, Yong M, van Kan M, de Zoysa JR, Burns KE.

Br J Clin Pharmacol. 2019 Sep;85(9):1925-1934. doi: 10.1111/bcp.14031. Epub 2019 Jul 22. Review.

PMID:
31218720
3.

Kidney Health Australia - Caring for Australasians with Renal Impairment guideline recommendations for infection control for haemodialysis units.

Jardine M, Commons RJ, de Zoysa JR, Wong MG, Gilroy N, Green J, Henderson B, Stuart RL, Tunnicliffe DJ, van Eps C, Athan E.

Nephrology (Carlton). 2019 Sep;24(9):951-957. doi: 10.1111/nep.13511. Epub 2019 Apr 29.

PMID:
30328179
4.

Predicting Outcome in Patients with Anti-GBM Glomerulonephritis.

van Daalen EE, Jennette JC, McAdoo SP, Pusey CD, Alba MA, Poulton CJ, Wolterbeek R, Nguyen TQ, Goldschmeding R, Alchi B, Griffiths M, de Zoysa JR, Vincent B, Bruijn JA, Bajema IM.

Clin J Am Soc Nephrol. 2018 Jan 6;13(1):63-72. doi: 10.2215/CJN.04290417. Epub 2017 Nov 21.

5.

A Trial of Extending Hemodialysis Hours and Quality of Life.

Jardine MJ, Zuo L, Gray NA, de Zoysa JR, Chan CT, Gallagher MP, Monaghan H, Grieve SM, Puranik R, Lin H, Eris JM, Zhang L, Xu J, Howard K, Lo S, Cass A, Perkovic V; ACTIVE Dialysis Steering Committee; Paul.

J Am Soc Nephrol. 2017 Jun;28(6):1898-1911. doi: 10.1681/ASN.2015111225. Epub 2017 Feb 1.

6.
7.

Metformin associated lactic acidosis in Auckland City Hospital 2005 to 2009.

Haloob I, de Zoysa JR.

World J Nephrol. 2016 Jul 6;5(4):367-71. doi: 10.5527/wjn.v5.i4.367.

8.

Update: Rationale and design of the Sodium Lowering In Dialysate (SoLID) trial: a randomised controlled trial of low versus standard dialysate sodium concentration during hemodialysis for regression of left ventricular mass.

Dunlop JL, Vandal AC, de Zoysa JR, Gabriel RS, Haloob IA, Hood CJ, Matheson PJ, McGregor DO, Rabindranath KS, Semple DJ, Marshall MR.

BMC Nephrol. 2015 Aug 1;16:120. doi: 10.1186/s12882-015-0080-y.

9.

Rationale and design of the Myocardial Microinjury and Cardiac Remodeling Extension Study in the Sodium Lowering in Dialysate trial (Mac-SoLID study).

Dunlop JL, Vandal AC, de Zoysa JR, Gabriel RS, Gerber LM, Haloob IA, Hood CJ, Irvine JH, Matheson PJ, McGregor DO, Rabindranath KS, Schollum JB, Semple DJ, Marshall MR.

BMC Nephrol. 2014 Jul 21;15:120. doi: 10.1186/1471-2369-15-120.

10.
11.

Extended high cut-off haemodialysis for myeloma cast nephropathy in Auckland, 2008-2012.

Tan J, Lam-Po-Tang M, Hutchison CA, de Zoysa JR.

Nephrology (Carlton). 2014 Jul;19(7):432-5. doi: 10.1111/nep.12267.

PMID:
24931113
12.

Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis.

Bose B, Badve SV, Hiremath SS, Boudville N, Brown FG, Cass A, de Zoysa JR, Fassett RG, Faull R, Harris DC, Hawley CM, Kanellis J, Palmer SC, Perkovic V, Pascoe EM, Rangan GK, Walker RJ, Walters G, Johnson DW.

Nephrol Dial Transplant. 2014 Feb;29(2):406-13. doi: 10.1093/ndt/gft378. Epub 2013 Sep 15. Review.

PMID:
24042021
13.

Rationale and design of the Sodium Lowering In Dialysate (SoLID) trial: a randomised controlled trial of low versus standard dialysate sodium concentration during hemodialysis for regression of left ventricular mass.

Dunlop JL, Vandal AC, de Zoysa JR, Gabriel RS, Haloob IA, Hood CJ, Matheson PJ, McGregor DO, Rabindranath KS, Semple DJ, Marshall MR.

BMC Nephrol. 2013 Jul 15;14:149. doi: 10.1186/1471-2369-14-149.

14.

Anti-glomerular basement membrane antibody disease is an uncommon cause of end-stage renal disease.

Tang W, McDonald SP, Hawley CM, Badve SV, Boudville NC, Brown FG, Clayton PA, Campbell SB, de Zoysa JR, Johnson DW.

Kidney Int. 2013 Mar;83(3):503-10. doi: 10.1038/ki.2012.375. Epub 2012 Dec 19.

15.

Lymphoma presenting as Henoch-Schönlein purpura.

Schena FP, Soerjadi N, Zwi J, de Zoysa JR.

Clin Kidney J. 2012 Dec;5(6):600-2. doi: 10.1093/ckj/sfs128. Epub 2012 Nov 6. No abstract available.

16.

End-stage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases.

Tang W, McDonald SP, Hawley CM, Badve SV, Boudville N, Brown FG, Clayton PA, Campbell SB, de Zoysa JR, Johnson DW.

Nephrol Dial Transplant. 2013 Feb;28(2):455-61. doi: 10.1093/ndt/gfs492. Epub 2012 Nov 25.

PMID:
23182810
17.

Vasculitis in New Zealand.

de Zoysa JR.

Clin Exp Nephrol. 2013 Oct;17(5):712-714. doi: 10.1007/s10157-012-0703-6. Epub 2012 Nov 23. Review.

PMID:
23180039
18.

Anti-glomerular basement membrane disease in Auckland.

Taylor DM, Yehia M, Simpson IJ, Thein H, Chang Y, de Zoysa JR.

Intern Med J. 2012 Jun;42(6):672-6. doi: 10.1111/j.1445-5994.2011.02621.x.

PMID:
22032242
19.

Troponins in acute kidney injury.

Song D, de Zoysa JR, Ng A, Chiu W.

Ren Fail. 2012;34(1):35-9. doi: 10.3109/0886022X.2011.623440. Epub 2011 Oct 20.

PMID:
22010639
20.

Hot flushes, hypertension and haemodialysis.

de Zoysa JR, Ng AK, Kim DD, Cranshaw IM, Croxson MS.

NDT Plus. 2011 Apr;4(2):110-2. doi: 10.1093/ndtplus/sfq210. Epub 2011 Jan 27.

21.

Nephrogenic systemic fibrosis, in patients with end-stage kidney disease on dialysis, in the greater Auckland region, from 2000-2006.

Kendrick-Jones JC, Voss DM, De Zoysa JR.

Nephrology (Carlton). 2011 Feb;16(2):243-8. doi: 10.1111/j.1440-1797.2010.01397.x.

PMID:
21272139
22.

Omeprazole-induced acute interstitial nephritis is not related to CYP2C19 genotype or CYP2C19 phenotype.

Helsby NA, Lo WY, Simpson IJ, Voss DM, Logan KE, Searle M, Schollum JB, de Zoysa JR.

Br J Clin Pharmacol. 2010 May;69(5):516-9. doi: 10.1111/j.1365-2125.2010.03623.x.

23.

Is computerized tomography useful in identifying abdominal catastrophes in patients presenting with peritonitis?

Yehia M, de Zoysa JR, Collins JF.

Perit Dial Int. 2008 Jul-Aug;28(4):385-90.

PMID:
18556381
24.

Podocyte biology in human disease.

de Zoysa JR, Topham PS.

Nephrology (Carlton). 2005 Aug;10(4):362-7. Review.

PMID:
16109083
25.

Cardiac troponins and renal disease.

De Zoysa JR.

Nephrology (Carlton). 2004 Apr;9(2):83-8. Review.

PMID:
15056267
26.

Casebook: proteinuria.

de Zoysa JR, Harris KP.

Practitioner. 2003 Nov;247(1652):860-2, 866, 870 passim. Review. No abstract available.

PMID:
14640049
27.

Successful treatment of CAPD peritonitis caused by rhodotorula mucilaginosa.

de Zoysa JR, Searle M, Lynn KL, Robson RA.

Perit Dial Int. 2001 Nov-Dec;21(6):627-8. No abstract available.

PMID:
11783780

Supplemental Content

Loading ...
Support Center